PRISMS Study

Clinical Trial Title

PRISMS: A phase IIIb, double-blind, multicenter study to evaluate the efficacy and safety of alteplase in patients with mild stroke, rapidly improving symptoms and minor neurological deficits

Clinical Trial Protocol Description:

The primary objective of this study is to determine the efficacy of IV alteplase for treatment of acute ischemic stroke in patients with mild stroke (also known as “minor neurologic deficit” and “rapidly improving stroke symptoms”) within three hours of last known well time.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are age ≥ 18 years (no upper age limit).
  • Have mild ischemic stroke.
  • Have the study treatment initiated within three hours of last known well time without stroke symptoms (i.e., last seen normal).
  • Have signed informed consent prior to initiation of any study-specific procedure or treatment.

This is a partial list of inclusion criteria.

Study Details

Clinical Trial Investigator

Sarah Song, MD

Contact Information

Tiffany Singson

(312) 563-2208